within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09D_AngiotensinIiReceptorBlockersArbsCombinations.C09DB09_FimasartanAndAmlodipine;
model FimasartanAndAmlodipine 
   extends Pharmacolibrary.Drugs.ATC.C.C09DB09;

  annotation(Documentation(
    info ="<html><body><p>Fimasartan and amlodipine is a fixed-dose combination of an angiotensin II receptor blocker (fimasartan) and a calcium channel blocker (amlodipine). This combination is used for the treatment of hypertension (high blood pressure) to reduce the risk of cardiovascular events. Both drugs are approved for use in several countries, including South Korea.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult male subjects after single oral administration of fixed-dose combination tablet containing fimasartan (60 mg) and amlodipine (10 mg).</p><h4>References</h4><ol><li><p>Rhee, SJ, et al., &amp; Yu, KS (2018). Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials. <i>Pharmaceutical research</i> 35(12) 236–None. DOI:<a href=&quot;https://doi.org/10.1007/s11095-018-2511-5&quot;>10.1007/s11095-018-2511-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30324316/&quot;>https://pubmed.ncbi.nlm.nih.gov/30324316</a></p></li><li><p>Jeon, SY, et al., &amp; Song, IS (2022). Simultaneous Analysis of a Combination of Anti-Hypertensive Drugs, Fimasartan, Amlodipine, and Hydrochlorothiazide, in Rats Using LC-MS/MS and Subsequent Application to Pharmacokinetic Drug Interaction with Red Ginseng Extract. <i>Toxics</i> 10(10) –. DOI:<a href=&quot;https://doi.org/10.3390/toxics10100576&quot;>10.3390/toxics10100576</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36287856/&quot;>https://pubmed.ncbi.nlm.nih.gov/36287856</a></p></li><li><p>Oh, M, et al., &amp; Shin, JG (2018). Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. <i>Drug design, development and therapy</i> 12 1157–1164. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S164215&quot;>10.2147/DDDT.S164215</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29780236/&quot;>https://pubmed.ncbi.nlm.nih.gov/29780236</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end FimasartanAndAmlodipine;
